AZ, Acerta report additional Phase II data for Calquence in MCL

AstraZeneca plc (LSE:AZN; NYSE:AZN) and Acerta Pharma B.V. (Oss, the Netherlands) reported additional data from the Phase II ACE-LY-004 trial in 124 patients with relapsed

Read the full 250 word article

User Sign In